Key Takeaways
- The HHS plans to reduce contract spending by 35% across all its divisions, impacting agencies like the FDA and NIH.
- Over 330 contracts have been terminated, raising concerns about the efficiency and effectiveness of public health services.
- Significant layoffs within HHS have accompanied these cuts, with calls for reinstatements following errors in job terminations.
HHS Implements Major Contract and Staffing Cuts
The Department of Health and Human Services (HHS) is planning to slash contract spending by 35% across all divisions, according to a statement provided to Fierce Biotech. An HHS representative emphasized the agency’s commitment to using resources more efficiently while maintaining its focus on public health improvement.
These cuts affect multiple agencies under HHS, including the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH). Reports indicate that at least 80 contracts related to diversity, equity, inclusion, and accessibility have been canceled since late January. Notable cancellations include partnerships with the Hispanic Association of Colleges and Universities and contracts with academic institutions like the University of Nebraska and the University of Alabama.
In addition to these specific contract terminations, HHS has cut over 254 contracts related to marketing, media, subscriptions, and consulting services. The HHS has not disclosed expected savings from these contract cancellations, leading to questions about the overall financial strategy.
The timing of these cuts comes amid significant job reductions within HHS. At the end of March, HHS head Robert F. Kennedy Jr. announced the layoff of 10,000 federal staff, which includes 3,500 full-time employees from the FDA and 1,200 from the NIH. An earlier reduction wave included 10,000 additional staffers through early retirements and other downsizing efforts. However, HHS officials later revealed that around 20% of the recent layoffs, roughly 2,000 employees, were mistakenly terminated, with plans for reinstatement in place.
These measures align with President Donald Trump’s executive order titled “Implementing the President’s ‘Department of Government Efficiency’ Workforce Optimization Initiative.” Along with the financial cuts, key leadership figures in health agencies have been replaced, exacerbating concerns about the future direction of services. Janet Woodcock, M.D., a former acting commissioner of the FDA, voiced serious concerns during an April 7 session of the Biopharma Congress. She remarked on the potential gaps in drug evaluation processes due to the significant leadership turnover, stressing that while document reviews would continue, the necessary infrastructure for timely drug market approval might be poorly affected.
Critics such as Robert Steinbrook, M.D., director of the health research group at Public Citizen, have expressed skepticism about the rapid implementation of cuts, fearing they may lead to more issues instead of constructive solutions. These developments raise critical questions about HHS’s capability to operate effectively amid such drastic changes to staffing and contracting practices.
The content above is a summary. For more details, see the source article.